Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in sarcoma and GIST
- Trial result Spotlight
Sarcoma and GIST
Abemaciclib (CDK4/6) + temozolomide/irinotecan delivers durable CR in 5th-relapse ARMS
Abemaciclib is an oral CDK4/6 inhibitor; in JPCS Part A (Phase 1b, NCT04238819) an 8-year-old with 5th-relapse, PAX3-FOXO1, CDK4-amplified ARMS received abemaciclib 55 mg/m² BID continuously with temozolomide 100…
NCT04238819 - New trial Spotlight
Sarcoma and GIST
Phase II nab-Sirolimus trial: nanoparticle albumin-bound mTOR inhibitor for epithelioid hemangioendothelioma.
Investigating nab-Sirolimus in a non-randomized, open-label, single-arm Phase II trial, Sarcoma Alliance for Research through Collaboration assesses the objective response rate by RECIST v1.1 in patients with…
NCT07104331 Exploratory - New trial
Sarcoma and GIST
Phase I trial: bland particles embolization with arterial occlusion for pediatric sarcomas
This phase I single-center, single-arm trial is evaluating the safety and feasibility of transarterial embolization using bland particles to occlude feeding vessels in hypervascular pediatric soft tissue sarcomas,…
NCT07136571 Exploratory - New trial
Sarcoma and GIST
Phase 2 Pembrolizumab PD-1 Inhibitor Study in Ultra-Rare Sarcomas
This minibasket study by Memorial Sloan Kettering assesses whether pembrolizumab—a PD-1 inhibitor that releases immune brakes—is safe and effective in ultra-rare sarcomas (including pleomorphic liposarcoma,…
NCT07089992 Exploratory - New trial
Sarcoma and GIST
Phase II Doxorubicin & Trabectedin Trial: DNA Synthesis and Tubulin Inhibition in Uterine Leiomyosarcoma
This Phase II single-arm study led by MD Anderson investigates the safety and efficacy of combining adjuvant doxorubicin (Topo II inhibitor) plus trabectedin (DNA-minor-groove binder) in patients with stage Ib-III…
NCT07076186 Exploratory - New trial Spotlight
Sarcoma and GIST
Phase 1 MBRT: tungsten‐slit collimator enables spatially fractionated minibeam radiation therapy
Investigating the safety and optimal dose of MBRT at Mayo Clinic, this study tests minibeam radiation—delivered via a tungsten slit collimator that creates alternating peak and valley dose regions—in patients with…
NCT07062003 First-in-human - New trial
Sarcoma and GIST
Phase 1 trial of 5-ALA, tumor‑targeted fluorescent imaging agent in sarcoma
This study evaluates whether oral 5-ALA (20 mg/kg), which is metabolized within tumor cells to emit fluorescence, can improve intraoperative visualization of soft tissue sarcomas in FNCLCC Grade 2 or 3 patients.…
NCT07038278 Exploratory - New trial
Sarcoma and GIST
Phase II Trial: Atezolizumab PD-L1 mAb + Doxorubicin DNA Synthesis Inhibitor in Soft Tissue Sarcoma
This Phase II study evaluates neoadjuvant, concurrent, and adjuvant administration of atezolizumab (a PD-L1 targeted monoclonal antibody) and doxorubicin (a micelle-formulated DNA synthesis inhibitor) combined with…
NCT07049848 Exploratory - Trial result
Sarcoma and GIST
Epirubicin/Ifosfamide + Nivolumab Hits 69% ORR in First-Line Undifferentiated Pleomorphic Sarcoma
Epirubicin (anthracycline; 60 mg/m² d1-2) and ifosfamide (3 g/m² d1-3) paired with the PD-1 inhibitor nivolumab (360 mg d3) were tested in 3-week cycles in the Spanish phase Ib ImmunoSarc2 cohort 7a (NCT03277924).…
NCT03277924 - New trial
Sarcoma and GIST
Phase II trial of pembrolizumab PD‑1 inhibitor in advanced cutaneous sarcoma
This single arm, open-label Phase II study evaluates pembrolizumab monotherapy given every 21 days in adult patients with advanced cutaneous sarcomas (excluding angiosarcoma). Sponsored by H. Lee Moffitt Cancer…
NCT07007273 - Trial result
Sarcoma and GIST
NB003 Broad-Spectrum KIT Inhibitor Delivers ≈43% ORR and 13.8-mo mPFS in 4th-Line GIST
NB003 is an oral tyrosine-kinase inhibitor engineered to hit both ATP-binding–site (ex13/14) and activation-loop (ex17/18) KIT resistance mutations that undercut imatinib and next-gen agents. In the phase 1…
NCT04936178 - Trial result
Sarcoma and GIST
Durvalumab (PD-L1) + doxorubicin boosts PFS to 8.2 mo in anthracycline-naïve soft-tissue sarcoma
Durvalumab, a PD-L1 inhibitor, 1500 mg plus topoisomerase II inhibitor doxorubicin 75 mg/m² Q3W was tested in the phase Ib/II NCT03798106 trial in 41 metastatic/recurrent STS patients with no prior anthracycline or…
NCT03798106 - New trial
Sarcoma and GIST
Phase II Study of Pomalidomide, Thalidomide Derivative Vascular Inhibitor in Kaposi Sarcoma
This trial evaluates pomalidomide monotherapy for Kaposi Sarcoma patients. Eligible participants receive pomalidomide orally in cycles, with treatment continuation based on response. Conducted at multiple US centers…
NCT04577755 - New trial
Sarcoma and GIST
Phase I trial: Zanzalintinib cMet/VEGFR inhibitor with checkpoint inhibitors.
This dose-finding study evaluates zanzalintinib combined with ipilimumab and nivolumab for metastatic soft tissue sarcoma in patients with progression on 2nd–4th line therapy. Conducted at Washington University…
NCT06968988 - Trial result
Sarcoma and GIST
Dendritic-Cell Vaccine Shows Durable Control in 20% of Metastatic Sarcoma, Tied to T-Cell–Rich Tumor Microenvironment
In a Phase I trial (NCT01803152), 19 patients with advanced or metastatic sarcoma received an autologous dendritic-cell vaccine after prior therapies; median PFS was 9.5 months, with 4 (21%) long-term responders (>2…
NCT01803152 - Trial result
Sarcoma and GIST
Anti-PD-L1 Avelumab + VEGFR TKI Axitinib Delivers 40% ORR in MMR-Proficient Endometrial Cancer
In a two-stage Phase 2 study (NCT02912572) anti-PD-L1 Avelumab plus the VEGFR1-3 tyrosine kinase inhibitor, axitinib, was evaluated in 35 patients with recurrent or persistent mismatch-repair-proficient endometrial…
NCT02912572 - Trial result
Sarcoma and GIST
Varegacestat (γ-Secretase Inhibitor) Shrinks Desmoid Tumors in 46–78% of Patients Across All Subgroups
In the RINGSIDE Phase 2 open label trial (NCT04871282), 42 adults with progressing desmoid tumors received the oral γ-Secretase Inhibitor, varegacestat 1.2 mg QD, 2 mg or 4 mg. (2 days on/5 off); median follow-up 23…
NCT04871282 - Trial result
Sarcoma and GIST
Ripretinib (switch-control KIT/PDGFRA TKI) matches sunitinib on survival in second-line GIST
Phase 3 INTRIGUE (NCT03673501) randomized 453 imatinib-refractory GIST patients to continuous-dose ripretinib 150 mg vs intermittent sunitinib 50 mg (4 wk on/2 wk off); after 211 deaths, median OS was 35.5 mo vs 31.5…
NCT03673501 - Trial result
Sarcoma and GIST
FAZ053 Monotherapy Shines in Rare Sarcomas Despite Combination Setbacks
In this first-in-human, phase I trial, FAZ053—an anti-PD-L1 monoclonal antibody—was evaluated as monotherapy and in combination with spartalizumab in 154 patients with advanced solid tumors. While around half of the…
- New trial
Sarcoma and GIST
Phase 1b/2 Study of ERAS-601 SHP2 Inhibitor as Monotherapy in Advanced Chordoma
Memorial Sloan Kettering is investigating whether ERAS-601, a SHP2 inhibitor, can safely and effectively treat advanced, progressing chordoma. The single-arm trial administers ERAS-601 at 40mg BID on a 3-weeks-on,…
NCT06957327 - New trial
Sarcoma and GIST
An Open-Label, Multicenter, Phase 2 Study with Safety Lead-In of Intratumoral VO Plus Pembrolizumab in Angiosarcoma
This phase 2 trial is evaluating the safety of intratumoral VO combined with pembrolizumab in patients with locally advanced or metastatic angiosarcoma who have progressed following prior immunotherapy, with an…
NCT06898970 - New trial
Sarcoma and GIST
Expanded Access: Bezuclastinib with Sunitinib in Advanced GIST
Cogent Biosciences, Inc. is offering investigational bezuclastinib in combination with sunitinib to patients with locally advanced, unresectable, or metastatic gastrointestinal stromal tumors who have no comparable…
NCT06948955 - New trial
Sarcoma and GIST
Phase 1/2 Study: ADCE-D01 in Advanced Soft Tissue Sarcoma
Adcendo ApS is evaluating ADCE-D01—a humanized anti-uPARAP antibody linked to a topoisomerase I inhibitor—to assess its safety, pharmacokinetics, and antitumor activity in patients with metastatic and/or unresectable…
NCT06797999 - Trial result
Sarcoma and GIST
FGFR Inhibition Shuts Down Tumor Growth in SDHd GIST, Offering a New Therapeutic Avenue
In preclinical models and a Phase II trial of rogaratinib in advanced SDHd GIST, FGFR inhibitors demonstrated significant tumor growth suppression and promising clinical activity with a 41.7% partial response rate…
- New trial
Sarcoma and GIST
Phase 1a/1b Study Combines Menin Inhibition with Imatinib in Advanced GIST
Kura Oncology is assessing the safety, tolerability, and initial efficacy of oral ziftomenib combined with imatinib in adults with advanced, KIT-mutant gastrointestinal stromal tumors post-imatinib failure. This…
NCT06655246 - New trial
Sarcoma and GIST
Preoperative Hypofractionated Radiotherapy Trial Targets Soft Tissue Sarcoma
The Medical University of South Carolina is testing a 5-day preoperative hypofractionated radiotherapy regimen using Gamma Tile brachytherapy to treat soft tissue sarcoma while preserving surrounding healthy tissue.…
NCT05512208
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.